Rapport Therapeutics (RAPP) Other Working Capital Changes (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Other Working Capital Changes of -$346000.0 for Q1 2026, down 778.43% year-over-year from $51000.0 in Q1 2025, and down 109.9% quarter-over-quarter from $3.5 million in Q4 2025.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Other Working Capital Changes (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Other Working Capital Changes for 4 consecutive years, with -$346000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 778.43% year-over-year to -$346000.0; the TTM figure through Mar 2026 stood at $3.2 million (up 252.24% YoY), while the FY2025 annual figure was $3.6 million, up 4433.73% from the prior year.
- Other Working Capital Changes eased to -$346000.0 in Q1 2026 per RAPP's latest filing, from $3.5 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $3.5 million in Q4 2025 and bottomed at -$2.1 million in Q2 2024.
- Historically, Other Working Capital Changes has averaged $158500.0 across 4 years, with a median of -$189000.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Working Capital Changes soared 11021.88% — and 2026, when it slumped 778.43%.
- Rapport Therapeutics' Other Working Capital Changes stood at -$1.1 million in 2023, then surged by 97.02% to -$32000.0 in 2024, then jumped by 11021.88% to $3.5 million in 2025, then tumbled by 109.9% to -$346000.0 in 2026.
- Business Quant data shows RAPP's Other Working Capital Changes at -$346000.0 in Q1 2026, $3.5 million in Q4 2025, and -$446000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Rapport Therapeutics | 2.17 Bn | 2.17 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Jun 30, 2026 | 3.16 Mn |
| Mar 31, 2026 | -814,000.00 |
| Mar 31, 2026 | -814,000.00 |
| Dec 31, 2025 | 987,000.00 |
| Dec 31, 2025 | 987,000.00 |
| Sep 30, 2025 | -2.53 Mn |
| Sep 30, 2025 | -2.53 Mn |
| Jun 30, 2025 | 4.32 Mn |
| Jun 30, 2025 | 4.32 Mn |
| Mar 31, 2025 | 825,000.00 |
| Mar 31, 2025 | 825,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | 672,000.00 |
| Sep 30, 2024 | 672,000.00 |
| Jun 30, 2024 | -900,000.00 |
| Jun 30, 2024 | -900,000.00 |
| Mar 31, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |